Infusion of a Lipid Emulsion Modulates AMPK and Related Proteins in Rat Liver, Muscle, and Adipose Tissues

Obesity

Volumn 18, Issue 6, 2010, Pages 1108-1115

  Anavi, Sarit ^a   Ilan, Erez ^a   Tirosh, Oren ^a   Madar, Zecharia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; LIPID EMULSION; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN PHOSPHATASE 2C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; ADIPONECTIN RECEPTOR; ISOENZYME; PHOSPHOPROTEIN PHOSPHATASE; PPARGC1A PROTEIN, RAT; PROTEIN; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; PHOSPHOPROTEIN PHOSPHATASE 2C;

ACCBETA GENE; ADIPOR1 GENE; ADIPOR2 GENE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME MODULATION; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION; INSULIN RESISTANCE; LIPID OVERSUPPLY; LIVER; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SKELETAL MUSCLE; SREBP1C GENE; ANIMAL; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; WISTAR RAT; DRUG EFFECT;

ACETYL-COA CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; FAT EMULSIONS, INTRAVENOUS; GENE EXPRESSION REGULATION; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; ISOENZYMES; LIVER; MALE; MUSCLE, SKELETAL; PHOSPHOPROTEIN PHOSPHATASES; PROTEINS; RATS; RATS, WISTAR; RECEPTORS, ADIPONECTIN; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS;

RATTUS; RATTUS NORVEGICUS;

EID: 77952957851     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.489     Document Type: Article

References (38)

1. Bricker LA, Greydanus DE,. The metabolic syndrome: a gathering challenge in a time of abundance. Adolesc Med State Art Rev 2008; 19: 475-497, ix.
2. Sheng L, Qian Z, Shi Y, et al., Crocetin improves the insulin resistance induced by high-fat diet in rats. Br J Pharmacol 2008; 154: 1016-1024.
3. Kraegen EW, Cooney GJ,. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008; 19: 235-241.
4. Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE,. AMP-activated protein kinase - The fat controller of the energy railroad. Can J Physiol Pharmacol 2006; 84: 655-665.
5. Towler MC, Hardie DG,. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341.
6. Lee WJ, Kim M, Park HS, et al., AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1. Biochem Biophys Res Commun 2006; 340: 291-295.
7. Jäger S, Handschin C, St-Pierre J, Spiegelman BM,. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc Natl Acad Sci USA 2007; 104: 12017-12022.
8. Carling D, Sanders MJ, Woods A,. The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes (Lond) 2008; 32 (Suppl 4): S55-S59.
9. Hawley SA, Boudeau J, Reid JL, et al., Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
10. Shen QW, Zhu MJ, Tong J, Ren J, Du M,. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by α-lipoic acid in C2C12 myotubes. Am J Physiol, Cell Physiol 2007; 293: C1395-C1403.
11. Momcilovic M, Hong SP, Carlson M,. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 2006; 281: 25336-25343.
12. Steinberg GR, Michell BJ, van Denderen BJ, et al., Tumor necrosis factor α-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006; 4: 465-474.
13. Klumpp S, Thissen MC, Krieglstein J,. Protein phosphatases types 2Cα and 2Cβ in apoptosis. Biochem Soc Trans 2006; 34: 1370-1375.
14. Yamauchi T, Nio Y, Maki T, et al., Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339.
15. Viollet B, Mounier R, Leclerc J, et al., Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 2007; 33: 395-402.
16. Viollet B, Foretz M, Guigas B, et al., Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol (Lond) 2006; 574: 41-53.
17. Li L, Yang G, Li Q, Tang Y, Li K,. High-fat- and lipid-induced insulin resistance in rats: the comparison of glucose metabolism, plasma resistin and adiponectin levels. Ann Nutr Metab 2006; 50: 499-505.
18. Bligh EG, Dyer WJ,. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
19. Geary N, Langhans W, Scharrer E,. Metabolic concomitants of glucagon-induced suppression of feeding in the rat. Am J Physiol 1981; 241: R330-R335.
20. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
21. Barnea M, Shamay A, Stark AH, Madar Z,. A high-fat diet has a tissue-specific effect on adiponectin and related enzyme expression. Obesity (Silver Spring) 2006; 14: 2145-2153.
22. Marley AE, Sullivan JE, Carling D, et al., Biochemical characterization and deletion analysis of recombinant human protein phosphatase 2Cα. Biochem J 1996; 320 (Pt 3): 801-806.
23. Zhou L, Deepa SS, Etzler JC, et al., Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 2009; 284: 22426-22435.
24. Lessard SJ, Rivas DA, Chen ZP, et al., Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes 2007; 56: 1856-1864.
25. Fediuc S, Gaidhu MP, Ceddia RB,. Regulation of AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation by palmitate in skeletal muscle cells. J Lipid Res 2006; 47: 412-420.
26. Watt MJ, Steinberg GR, Chen ZP, Kemp BE, Febbraio MA,. Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J Physiol (Lond) 2006; 574: 139-147.
27. Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC,. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 2008; 49: 407-416.
28. Kraegen EW, Saha AK, Preston E, et al., Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006; 290: E471-E479.
29. Ilan E, Tirosh O, Madar Z,. Triacylglycerol-mediated oxidative stress inhibits nitric oxide production in rat isolated hepatocytes. J Nutr 2005; 135: 2090-2095.
30. Klumpp S, Selke D, Hermesmeier J,. Protein phosphatase type 2C active at physiological Mg2+: stimulation by unsaturated fatty acids. FEBS Lett 1998; 437: 229-232.
31. Bonnard C, Durand A, Vidal H, Rieusset J,. Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diabetes Metab 2008; 34: 52-61.
32. Bullen JW Jr, Bluher S, Kelesidis T, Mantzoros CS,. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2007; 292: E1079-E1086.
33. Hribal ML, Oriente F, Accili D,. Mouse models of insulin resistance. Am J Physiol Endocrinol Metab 2002; 282: E977-E981.
34. Essop MF, Camp HS, Choi CS, et al., Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice. Am J Physiol Heart Circ Physiol 2008; 295: H256-H265.
35. Shi Y, Burn P,. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004; 3: 695-710.
36. Lavoie JM, Gauthier MS,. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006; 63: 1393-1409.
37. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al., A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846-860.
38. Yamazaki Y, Kakizaki S, Takizawa D, et al., Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2008; 23: 276-282.